Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection
Journal of Clinical Virology, Volume 156, Article 105273, Year 2022
Notification
URL copied to clipboard!
Description
Background: BA.2.12.1, BA.4 and BA.5 subvariants of SARS-CoV-2 variant-of-concern (VOC) Omicron (B.1.1.529) are spreading globally. They demonstrate higher transmissibility and immune escape. Objectives: Determine BA.2.12.1, BA.4 and BA.5 virus plaque reduction neutralization test (PRNT) antibody titres in individuals recently vaccinated with BNT162b2 (n = 20) or CoronaVac (n = 20) vaccines or those convalescent from ancestral wild- type (WT) SARS-CoV-2 (n = 20) or BA.2 infections with (n = 17) or without (n = 7) prior vaccination. Results: Relative to neutralization of the WT virus, those vaccinated with BNT162b2 had 4.8, 3.4, 4.6, 11.3 and 15.5-fold reductions of geometric mean antibody titres (GMT) to BA.1, BA.2, BA.2.12.1, BA.4 and BA.5 viruses, respectively. Similarly, those vaccinated with CoronaVac had 8.0, 7.0, 11.8, 12.0 and 12.0 fold GMT reductions and those with two doses of CoronaVac boosted by BNT162b2 had 6.1, 6.7, 6,3, 13.0 and 21.2 fold GMT reductions to these viruses, respectively. Vaccinated individuals with BA.2 breakthrough infections had higher GMT antibody levels vs. BA.4 (36.9) and BA.5 (36.9) than unvaccinated individuals with BA.2 infections (BA.4 GMT 8.2; BA.5 GMT 11.0). Conclusions: BA.4 and BA.5 subvariants were less susceptible to BNT162b2 or CoronaVac vaccine elicited antibody neutralization than subvariants BA.1, BA.2 and BA.2.12.1. Nevertheless, three doses BNT162b2 or booster of BNT162b2 following two doses of CoronaVac elicited detectable BA.4 and BA.5 neutralizing antibody responses while those vaccinated with three doses of CoronaVac largely fail to do so. BA.2 infections in vaccinated individuals led to higher levels of BA.4 or BA.5 neutralizing antibody compared to those who were vaccine-naive. © 2022
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC9428331/bin/mmc1.docx
Authors & Co-Authors
Cheng, Samuel M.S.
Hong Kong, Hong Kong
The University of Hong Kong
Mok, Ka Pun Chris
Hong Kong, Hong Kong
Chinese University of Hong Kong
Jeevan, Trushar
United States, Memphis
St. Jude Children's Research Hospital
Kandeil, A. Mohamed
United States, Memphis
St. Jude Children's Research Hospital
Pekosz, Andrew S.
United States, Baltimore
Johns Hopkins Bloomberg School of Public Health
Ko, Fanny Wai San
Hong Kong, Hong Kong
Chinese University of Hong Kong
Webby, Richard John
United States, Memphis
St. Jude Children's Research Hospital
Poon, Leo Lit Man
Hong Kong, Hong Kong
The University of Hong Kong
Hui, David Shu Cheong
Hong Kong, Hong Kong
Chinese University of Hong Kong
Peiris, Joseph Sriyal Malik
Hong Kong, Hong Kong
The University of Hong Kong
Hong Kong, Hong Kong
Hong Kong Science Park
Statistics
Citations: 17
Authors: 10
Affiliations: 5
Identifiers
Doi:
10.1016/j.jcv.2022.105273
ISSN:
13866532